Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials

Masataka Kuwana,1 Hiroshi Watanabe,2 Nobushige Matsuoka,3 Naonobu Sugiyama4

ABSTRACT

Objectives: Few studies have focused on pulmonary arterial hypertension (PAH) associated with connective tissue diseases (CTDs). The optimal treatment for CTD-PAH has yet to be established.

Design: Meta-analysis of the data from evaluations of treatment for PAH generally (19 studies) and CTD-PAH specifically (nine studies) to compare the effects of pulmonary vasodilative PAH agents. MEDLINE, EMBASE and BIOSIS were searched. English-language full-text articles published between January 1990 and August 2012 were eligible.

Setting: International.

Participants: Patients with PAH generally (n=3073) and CTD-PAH specifically (n=678).

Primary outcome measure: Exercise capacity (6 min walk distance, 6 MWD).

Results: Patients with PAH (all forms) had mean age 45–55 years (women, 61–87%); CTD-PAH patients had mean age 45–55 years (women, 74–95%). Overall estimate of mean change in 6 MWD from baseline (95% CI) for the active treatment group versus the control group in all patients with PAH was 34.6 m (27.4–41.9 m). Pooled mean differences from the results for patients receiving placebo by subgroup of patients receiving phosphodiesterase (PDE)-5 inhibitors, endothelin receptor antagonists (ERAs) and prostacyclin (PGI2) analogues were 22.4–45.5, 39.5–44.2 and 12.4–64.9 m, respectively. Overall estimate of mean difference between changes in 6 MWD in patients with CTD-PAH was 34.2 m (23.3–45.0 m). Pooled mean differences by subgroup of patients receiving PDE-5 inhibitors, ERAs and PGI2 analogues in patients with CTD-PAH were 37.0–47.1, 14.1–21.7 and 21.0–108.0 m, respectively. ERAs were less effective in patients with CTD-PAH than all-form patients with PAH: 14.1 m (–4.4–32.6 m) vs 39.5 m (19.5–59.6 m) for bosentan and 21.7 m (2.2–41.3 m) vs 44.2 m (30.2–58.2 m) for ambrisentan.

Conclusions: All three types of PAH agent are effective. However, ERAs may be a less effective choice against CTD-PAH; further studies are needed. Limitations include the limited number of studies for some agents and for patients with CTD-PAH.

ARTICLE SUMMARY

Article focus

Pulmonary arterial hypertension (PAH) is a progressive disease characterised by abnormally high blood pressure in the pulmonary arteries.

Patients with PAH associated with connective tissue diseases (CTDs) such as systemic sclerosis (SSc) have a particularly poor prognosis.

Few studies have focused on patients with CTD-PAH, so the optimal treatment for these patients is unclear.

Key messages

The effects of the phosphodiesterase-5 inhibitors sildenafil and tadalafil, and the prostacyclin analogue epoprostenol, are consistent in patients with CTD-PAH and in those with PAH generally.

The endothelin receptor antagonists bosentan and ambrisentan may be less effective in patients with CTD-PAH than in those with PAH generally.

Strengths and limitations of this study

The meta-analysis used all currently available data from clinical studies on treatment for PAH.

Few studies were identified for some PAH agents and for patients with CTD-PAH.

Study designs and patient background characteristics, including the percentages of patients with SSC–PAH, were inconsistent between studies.

INTRODUCION

Pulmonary hypertension is a heterogeneous condition with sustained elevation of pressure in the pulmonary arteries, and is defined as mean pulmonary artery pressure ≥25 mm Hg at rest.1 The most recent and widely accepted clinical classification of pulmonary hypertension is that proposed at the Fourth World Symposium on Pulmonary Hypertension at Dana Point in 2008.2 It classifies pulmonary hypertension into five groups. Group 1 comprises pulmonary arterial hypertension (PAH), which includes idiopathic PAH, heritable PAH, drug-induced and toxin-induced PAH, PAH associated with connective tissue disease, and PAH associated with HIV. Group 2 comprises PAH associated with left heart disease.

ARTICLE SUMMARY

ABSTRACT

Objectives: Few studies have focused on pulmonary arterial hypertension (PAH) associated with connective tissue diseases (CTDs). The optimal treatment for CTD-PAH has yet to be established.

Design: Meta-analysis of the data from evaluations of treatment for PAH generally (19 studies) and CTD-PAH specifically (nine studies) to compare the effects of pulmonary vasodilative PAH agents. MEDLINE, EMBASE and BIOSIS were searched. English-language full-text articles published between January 1990 and August 2012 were eligible.

Setting: International.

Participants: Patients with PAH generally (n=3073) and CTD-PAH specifically (n=678).

Primary outcome measure: Exercise capacity (6 min walk distance, 6 MWD).

Results: Patients with PAH (all forms) had mean age 45–55 years (women, 61–87%); CTD-PAH patients had mean age 45–55 years (women, 74–95%). Overall estimate of mean change in 6 MWD from baseline (95% CI) for the active treatment group versus the control group in all patients with PAH was 34.6 m (27.4–41.9 m). Pooled mean differences from the results for patients receiving placebo by subgroup of patients receiving phosphodiesterase (PDE)-5 inhibitors, endothelin receptor antagonists (ERAs) and prostacyclin (PGI2) analogues were 22.4–45.5, 39.5–44.2 and 12.4–64.9 m, respectively. Overall estimate of mean difference between changes in 6 MWD in patients with CTD-PAH was 34.2 m (23.3–45.0 m). Pooled mean differences by subgroup of patients receiving PDE-5 inhibitors, ERAs and PGI2 analogues in patients with CTD-PAH were 37.0–47.1, 14.1–21.7 and 21.0–108.0 m, respectively. ERAs were less effective in patients with CTD-PAH than all-form patients with PAH: 14.1 m (–4.4–32.6 m) vs 39.5 m (19.5–59.6 m) for bosentan and 21.7 m (2.2–41.3 m) vs 44.2 m (30.2–58.2 m) for ambrisentan.

Conclusions: All three types of PAH agent are effective. However, ERAs may be a less effective choice against CTD-PAH; further studies are needed. Limitations include the limited number of studies for some agents and for patients with CTD-PAH.

INTRODUCION

Pulmonary hypertension is a heterogeneous condition with sustained elevation of pressure in the pulmonary arteries, and is defined as mean pulmonary artery pressure ≥25 mm Hg at rest.1 The most recent and widely accepted clinical classification of pulmonary hypertension is that proposed at the Fourth World Symposium on Pulmonary Hypertension at Dana Point in 2008.2 It classifies pulmonary hypertension into five groups. Group 1 comprises pulmonary arterial hypertension (PAH), which includes idiopathic PAH, heritable PAH, drug-induced and toxin-induced PAH, PAH associated with connective tissue disease, and PAH associated with HIV. Group 2 comprises PAH associated with left heart disease.
various diseases and persistent pulmonary hypertension of the newborn. Group 2 comprises pulmonary hypertension owing to left heart disease; group 3, pulmonary hypertension owing to lung diseases and/or hypoxia; group 4, chronic thromboembolic pulmonary hypertension; and group 5, pulmonary hypertension of unknown cause. In this classification of pulmonary hypertension, PAH is recognised as having an extremely poor prognosis and requires specific medical treatment.

Connective tissue disease (CTD) is the most common condition associated with PAH. Recent cohort studies have shown that most patients with PAH associated with CTD have systemic sclerosis (SSc).\(^3\) In fact, the prevalence of PAH in patients with SSc is reported to be 7–12%.\(^5\) Patients with SSc–PAH have poor prognosis compared with patients with idiopathic PAH.\(^7\) Therefore, early and appropriate diagnosis and selection of the optimal treatment regimen are important for SSc–PAH, to improve the hemodynamics, exercise capacity and eventually survival of patients.

The optimal treatment for PAH has not been established. However, there has been major progress in medical treatment for PAH in recent years. Several new agents with different mechanisms have been introduced, including phosphodiesterase (PDE)-5 inhibitors (eg, oral sildenafil and tadalafil), endothelin receptor antagonists (ERAs) (eg, oral bosentan and ambrisentan) and prostacyclin (PGI\(_2\)) analogues (eg, continuous intravenous epoprostenol). The introduction of these new agents is expected to contribute to the improvement of exercise capacity, subjective symptoms and quality of life, as well as the short-term and long-term survival of patients.

Although the efficacy and safety of these new agents have been shown in small-scale or medium-scale randomised controlled trials (RCTs) and open-label trials, evidence from large-scale comparative studies of these agents remains insufficient because PAH is a rare disease. Therefore, to compare the new agents and establish a therapeutic strategy for PAH, several systematic reviews and meta-analyses of available clinical study results have been done.\(^8\)–\(^13\) However, most of these analyses include studies on all forms of PAH, and studies that focus on CTD-PAH are limited. In fact, our literature search showed only one such report: a meta-analysis by Avouac et al,\(^6\) which investigated the efficacy of oral PAH agents mainly in patients with SSc.

Therefore, in this meta-analysis of studies designed as RCTs and open-label, single-arm trials, we aimed to evaluate the effect of each PAH agent on exercise capacity in patients with CTD-PAH compared with patients with all forms of PAH. We chose 6 min walk distance (6 MWD) as an endpoint because it was used as a primary endpoint in most previous randomised studies of PAH agents.\(^14\)

METHODS

Eligibility criteria
To evaluate the effects of three typical types of PAH agent, we included RCTs in which the following PAH agents were administered to patients with all forms of PAH.

- PDE-5 inhibitors: sildenafil and tadalafil
- ERAs: bosentan and ambrisentan
- PGI\(_2\) analogues: epoprostenol, beraprost, iloprost and treprostinil.

Because the number of RCTs in patients with CTD-PAH is limited, we also included open-label, single-arm trials evaluating the effects of PAH agents in patients with CTD-PAH.

We excluded reviews and non-interventional studies (eg, case reports and observational studies as opposed to RCTs). We included only principal studies and excluded ad hoc analyses. Studies in which results for 6 MWD were not reported were also excluded, as were studies on pulmonary hypertension other than PAH.

Search strategy
We searched MEDLINE, EMBASE and BIOSIS for English-language full-text articles published between January 1990 and August 2012, using the key terms ‘pulmonary arterial hypertension’, ‘6 min walk’ and the names of individual drugs. In addition to these key terms, we used the term ‘randomised controlled trial’ or ‘RCT’ to identify RCTs evaluating all forms of PAH, and ‘connective tissue disease’ or ‘CTD’ to identify studies evaluating CTD-PAH. The last search was run on 5 December 2012. Additional studies were identified through manual searching.

Primary endpoint
The primary outcome measure was the difference in mean change from baseline in 6 MWD between groups. However, for single-arm studies, the mean change from baseline was used as the primary outcome measure.

Data collection
Relevant data were extracted and reviewed by NM and NS. Data on study characteristics (year and design), variables including PAH agents used, total patient numbers and the percentage of patients with CTD-PAH and outcomes (mean difference, m and 95% CI, m or SE) were extracted.

Risk of bias
To determine the validity of the included studies, we assessed the risk of bias for each study in terms of random sequence generation, allocation concealment, blinding and other sources of bias, as recommended by the Cochrane Collaboration. Each domain was judged to have high, low or unclear risk of bias. We did not detect clear publication bias, because the number of included studies was small.

Statistical analysis
We pooled outcomes by each PAH agent for all forms of PAH and for CTD-PAH. We used a random effects model based on the DerSimonian-Laird method...
because of known clinical and methodological heterogeneity (eg, the various doses of each PAH agent). The $I^2$ values were calculated as a measure of heterogeneity. The $I^2$ statistic, which describes the percentage of variability in effect estimates that is due to heterogeneity rather than sampling error (chance), and we considered $I^2 > 75\%$ as representing considerable heterogeneity.

RESULTS

Selection of studies

A total of 196 articles were identified for evaluation of treatments for all forms of PAH. Of these, 19 articles (reporting data from 3073 patients) met the eligibility criteria for evaluations of treatments for all forms of PAH (3 articles for sildenafil,15–17 1 article for tadalafil,18 4 articles for bosentan,19–22 1 article for ambrisentan,23 3 articles for epoprostenol,24–26 1 article for beraprost,27 2 articles for iloprost28 29 and 4 articles for treprostinil30–33; figure 1A). The main reasons for exclusion were that the article was a review and that the article reported the results of a study that involved patients other than those with PAH.

For evaluation of treatments for CTD-PAH, a total of 269 articles were identified. Of these, nine articles (reporting data from 678 patients) met the eligibility criteria for evaluations of treatments for CTD-PAH (1 article for sildenafil,34 1 article for tadalafil18 2 articles for bosentan35 36 2 articles for ambrisentan,37 38 1 article for epoprostenol,26 1 article for beraprost39 and 1 article for treprostinil40; figure 1B). The main reasons for exclusion were that the article was a review and that the article reported the results of a study that involved patients other than those with CTD-PAH.

Characteristics and overview of the included studies

Of the 19 studies on treatments for all forms of PAH included in this analysis (table 1), 15 were randomised, placebo-controlled, double-blind studies15–25 27 28 30–33; 3 were randomised, open-label studies comparing with conventional treatment24–26; and 1 was a randomised, open-label study evaluating the effects of iloprost when added to bosentan.29 The observation period was either 12 or 16 weeks in most of the studies, with some exceptions (one study each with 6-week and 24-week observation periods16 22 and two studies with an 8-week observation period24 31). Of the placebo-controlled randomised comparative studies, one study of sildenafil was performed in patients previously treated with epoprostenol17; two studies of iloprost, in patients previously treated with bosentan28 29; and one study of treprostinil, in patients previously treated with bosentan or sildenafil.32

Of the nine studies on treatments for CTD-PAH included in this analysis (table 2), five were placebo-controlled, double-blind studies,18 34 35 37 40 one was a randomised, open-label study comparing with conventional treatment26 and three were open-label, single-arm studies.36 38 39 The observation period in these studies was 8–28 weeks. One study each evaluating bosentan,36 and epoprostenol26 included only patients with SSc-PAH.

Background of all patients with PAH

The background of all patients with PAH, based on data from the 19 studies, can be summarised as follows (full data in online supplementary table S1). Mean age was 32–55 years, and the percentage of women was 61–87%. In the studies of sildenafil15–17 tadalafil18 bosentan,19–22 ambrisentan23 and beraprost,27 most patients were classified according to WHO functional class (WHO-FC) as in WHO-FC II or III, with one study including only patients in WHO-FC II.24 In contrast, in the studies of epoprostenol24–26 the percentage of patients in WHO-FC IV was higher than that in studies of other agents. In the studies of iloprost, most patients were in WHO-FC IV28 29 In the studies of treprostinil, most patients were in WHO-FC III in three studies30 32 35 and in WHO-FC II in one study.31 Baseline 6 MWD was 226.6–434.5 m, and it was lower in the three studies of epoprostenol (226.6, 294.3 and 255.9 m)24–26 compared with in studies on other agents. Therefore, patients with more severe disease were included in the studies of epoprostenol than in other studies. One study of bosentan included only patients with Eisenmenger syndrome.21

Background of the subgroup of patients with CTD-PAH

Of the nine studies on patients with CTD-PAH, using data from nine studies, can be summarised as follows (full data in online supplementary table S2). Mean age was 45–55 years, and the percentage of women was 74–95%. In one study of tadalafil, there was no information on baseline 6 MWD or WHO-FC.18 As for the distribution of patients according to WHO-FC, a study of beraprost included more patients in WHO-FC II,39 and a study of epoprostenol included more patients in WHO-FC IV26 compared with studies of other agents.

In five studies in which information on underlying CTDs was available, patients with SSc-PAH accounted for 45–100% of all patients included. Their mean age was 51–55 years, and the percentage of women was 74–90%.

In studies of bosentan36 and epoprostenol26 that included only patients with SSc-PAH, baseline 6 MWD was <300 m, which was lower than that in studies of other agents. Therefore, the study of beraprost included more patients with relatively mild PAH, whereas the study of epoprostenol included more patients with more severe disease.

Results of 6 MWD

The actual values of the outcomes for each study are presented on the right side of figures 2 and 3. We pooled the data, including those for non-approved doses, to evaluate the effect of each PAH agent on exercise capacity in patients with CTD-PAH compared with in patients with all forms of PAH.
6 MWD in all patients with PAH

The mean differences between changes in 6 MWD compared with the control group are shown in figure 2 by each agent. With a random effects model, the pooled mean difference between changes in 6 MWD was 45.5 m (95% CI 32.9 to 58.1 m, $I^2=50.1\%$) for sildenafil, 22.4 m (95% CI 14.0 to 30.9 m, $I^2=47.9\%$) for tadalafil, 39.5 m (95% CI 19.5 to 59.6 m, $I^2=38.3\%$) for bosentan, 44.2 m (95% CI 30.2 to 58.2 m, $I^2=0\%$) for ambrisentan, 64.9 m (95% CI 20.4 to 109.4 m, $I^2=43.3\%$) for epoprostenol, 25.1 m (95% CI 1.9 to 48.4 m, $I^2=0\%$ for beraprost, 12.4 m (95% CI $-21.9$ to 46.6 m, $I^2=39.7\%$) for iloprost, and 17.3 m (95% CI 6.1 to 28.4 m, $I^2=29.4\%$) for treprostinil. Numerical improvement in 6 MWD was obtained in patients using each agent compared with those using the control agent. The pooled mean difference between changes in 6 MWD from the control group ranged from 12.4 to 64.9 m, and the overall estimate of mean difference was 34.6 m (95% CI 27.4 to 41.9 m, $I^2=63.2\%$). The ranges of mean differences by subgroup of patients receiving PDE-5 inhibitors, ERAs and PGI2 analogues were 22.4–45.5, 14.1–21.7 and 12.4–64.9 m, respectively. Considerable heterogeneity was not observed.

6 MWD in a subgroup of patients with CTD-PAH

In the subgroup of patients with CTD-PAH, the mean differences between changes in 6 MWD compared with the control group are shown in figure 3 by each agent. For single-arm studies, the mean changes from baseline are shown. With a random effects model, the pooled mean difference between changes in 6 MWD was 47.1 m (95% CI 27.9 to 66.3 m, $I^2=0\%$) for sildenafil, 30.2 m (95% CI 19.5 to 55.0 m, $I^2=0\%$) for tadalafil, 21.7 m (95% CI 2.2 to 41.3 m, $I^2=0\%$) for ambrisentan, 108.0 m (95% CI 45.6 to 170.4 m, $I^2=NA$) for epoprostenol, 58.5 m (95% CI 21.4 to 95.6 m, $I^2=NA$) for beraprost and 21.0 m (95% CI $-6.9$ to 48.9 m, $I^2=0\%$) for treprostinil. Numerical improvement in 6 MWD was obtained in patients using all agents compared with those using the control agent. The overall estimate of mean difference between changes in 6 MWD in patients with CTD-PAH was 34.2 m (95% CI 23.3 to 45.0 m, $I^2=32.5\%$). The ranges of mean differences by subgroup of patients receiving PDE-5 inhibitors, ERAs and PGI2 analogues were 37.0–47.1, 19.0–22.1 and 21.0–108.0 m, respectively. Considerable heterogeneity was not observed.

We did an additional sensitivity analysis excluding open-label single-arm studies for patients with CTD-PAH only (see online supplementary figure). The overall estimate of mean difference between changes in 6 MWD in patients with CTD-PAH was 37.2 m (95% CI 25.0 to 49.3 m, $I^2=20.5\%$) and the ranges of mean differences by subgroup of patients receiving PDE-5 inhibitors, ERAs and PGI2 analogues were 37.0–47.1, 19.0–21.7 and 21.0–108.0 m, respectively.

Difference in exercise capacity between all patients with PAH and CTD-PAH

When the pooled mean differences between changes in 6 MWD were compared between all patients with PAH and each subgroup of patients with CTD-PAH, no difference in exercise capacity was found between the patient groups for PDE-5 inhibitors (sildenafil and tadalafil). In contrast, for ERAs (bosentan and ambrisentan), the pooled mean values in patients with CTD-PAH (bosentan, 14.1 m; ambrisentan, 21.7 m) were lower than the lower limit of 95% CI of the mean values in all patients with PAH (bosentan 19.5–59.6 m; ambrisentan 30.2–58.2 m), suggesting that effects on exercise capacity may vary between patient groups. For PGI2 (epoprostenol,
Table 1  Summary of included studies evaluating treatment with PAH agents in patients with all forms of PAH

<table>
<thead>
<tr>
<th>Source (official acronym)</th>
<th>PAH agent</th>
<th>Number of patients</th>
<th>Number (%) of CTD-PAH patients</th>
<th>Study design</th>
<th>Intervention</th>
<th>Control</th>
<th>Period (weeks)</th>
<th>Results for CTD-PAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galiè et al(^1) (SUPER-1)</td>
<td>Sildenafil</td>
<td>278</td>
<td>84 (30)</td>
<td>RCT, DB</td>
<td>20 mg×3/day, 40 mg×3/day and 80 mg×3/day</td>
<td>Placebo</td>
<td>12</td>
<td>Available in Badesch et al(^4)</td>
</tr>
<tr>
<td>Singh et al(^6)</td>
<td>Sildenafil</td>
<td>20</td>
<td>0</td>
<td>RCT, DB</td>
<td>25 mg on first day, then if no hypotension, 100 mg×3/day</td>
<td>Placebo</td>
<td>6</td>
<td>None</td>
</tr>
<tr>
<td>Simonneau et al(^7) (PACES)</td>
<td>Sildenafil</td>
<td>267</td>
<td>55 (21)</td>
<td>RCT, DB</td>
<td>20 mg×3/day, titrated to 40 mg and 80 mg×3/day, as tolerated, at 4-week intervals on background treatment with epoprostenol</td>
<td>Placebo on background treatment with epoprostenol</td>
<td>16</td>
<td>None</td>
</tr>
<tr>
<td>Galiè et al(^8) (PHIRST)</td>
<td>Tadalafil</td>
<td>405</td>
<td>95 (24)</td>
<td>RCT, DB</td>
<td>2.5, 10, 20 and 40 mg</td>
<td>Placebo</td>
<td>16</td>
<td>Available in this article</td>
</tr>
<tr>
<td>Channick et al(^9)</td>
<td>Bosentan</td>
<td>32</td>
<td>5 (16)</td>
<td>RCT, DB</td>
<td>62.5 mg×2/day for 4 weeks, then 125 mg×2/day</td>
<td>Placebo</td>
<td>12</td>
<td>None</td>
</tr>
<tr>
<td>Rubin et al(^10) (BREATHE-1)</td>
<td>Bosentan</td>
<td>213</td>
<td>63 (30)</td>
<td>RCT, DB</td>
<td>62.5 mg×2/day for 4 weeks, then 125 mg or 250 mg×2/day</td>
<td>Placebo</td>
<td>16</td>
<td>Available in Denton et al(^35)</td>
</tr>
<tr>
<td>Galiè et al(^11) (BREATHE-5)</td>
<td>Bosentan</td>
<td>54</td>
<td>0</td>
<td>RCT, DB</td>
<td>62.5 mg×2/day for 4 weeks, then 125 mg×2/day</td>
<td>Placebo</td>
<td>16</td>
<td>None</td>
</tr>
<tr>
<td>Galiè et al(^12) (EARLY)</td>
<td>Bosentan</td>
<td>185</td>
<td>33 (18)</td>
<td>RCT, DB</td>
<td>62.5 mg×2/day for 4 weeks, then 125 mg×2/day</td>
<td>Placebo</td>
<td>24</td>
<td>None</td>
</tr>
<tr>
<td>Galiè et al(^13) (ARIES)</td>
<td>Ambrisentan</td>
<td>393</td>
<td>124 (32)</td>
<td>RCT, DB</td>
<td>2.5, 5 and 10 mg</td>
<td>Placebo</td>
<td>12</td>
<td>Available in Badesch(^37)</td>
</tr>
<tr>
<td>Rubin et al(^14)</td>
<td>Epoprostenol</td>
<td>23</td>
<td>0</td>
<td>RCT, open-label</td>
<td>Initial dosage of 1–2 ng/kg/min, then titrated to an optimal dose</td>
<td>Conventional therapy</td>
<td>8</td>
<td>None</td>
</tr>
<tr>
<td>Barst et al(^15)</td>
<td>Epoprostenol</td>
<td>81</td>
<td>0</td>
<td>RCT, open-label</td>
<td>Initial dosage of 2 ng/kg/min, then titrated to optimal dosage</td>
<td>Conventional therapy</td>
<td>12</td>
<td>None</td>
</tr>
<tr>
<td>Badesch et al(^16)</td>
<td>Epoprostenol</td>
<td>111</td>
<td>111 (100)</td>
<td>RCT, open-label</td>
<td>Dosage established according to signs and symptoms from an initial low dose</td>
<td>Conventional therapy</td>
<td>12</td>
<td>Available in this article</td>
</tr>
<tr>
<td>Galiè et al(^17) (ALPHABET)</td>
<td>Beraprost</td>
<td>130</td>
<td>13 (10)</td>
<td>RCT, DB</td>
<td>20 mg×4/day for first week, then titrated to 120 mg×4/day</td>
<td>Placebo</td>
<td>12</td>
<td>None</td>
</tr>
<tr>
<td>McLaughlin et al(^18) (STEP)</td>
<td>Inhaled iloprost</td>
<td>67</td>
<td>NR</td>
<td>RCT, DB</td>
<td>5 mg on background treatment with bosentan (125 mg×2/day)</td>
<td>Placebo on background treatment with bosentan (125 mg×2/day)</td>
<td>12</td>
<td>None</td>
</tr>
<tr>
<td>Hoeper et al(^19) (COMBI)</td>
<td>Inhaled iloprost</td>
<td>40</td>
<td>0</td>
<td>RCT, open-label</td>
<td>5 mg on background treatment with bosentan (125 mg×2/day)</td>
<td>Placebo on background treatment</td>
<td>12</td>
<td>None</td>
</tr>
</tbody>
</table>

Continued
beraprost and treprostinil), no obvious trends were found between patient groups.

**Risk of bias**

We rated risk of bias for each study (full data in online supplementary table S3). In studies for all forms of PAH, none were at high risk of bias for random sequence generation or allocation concealment; however, the method of randomisation and allocation concealment were unclear (ie, not reported) for 11 and 9 studies, respectively. Four studies were at high risk of bias for blinding because they were open-label studies. Three studies were at high risk for another source of bias (imbalance in missing data between groups, imbalance in baseline 6 MWD and early termination based on futility analysis).

Of studies for CTD-PAH, three studies were at high risk of bias with respect to all domains because they were open-label, single-arm studies. One study was at high risk of bias resulting from imbalance in baseline characteristics. The remaining studies were judged to be not of high risk of bias in any of the domains.

**DISCUSSION**

A finding of the present meta-analysis of 19 studies is that in combined patients with all forms of PAH, all agents increase 6 MWD compared with the control group. Likewise, the meta-analysis of nine studies on patients with CTD-PAH also showed an increase in 6 MWD by all agents. The finding that all agents increase 6 MWD in all patients with PAH is consistent with the results of the five previous systematic reviews and meta-analyses that evaluated the three types of agent (PDE-5 inhibitors, ERAs and PGI2 analogues). To date, reports of meta-analyses that included patients with CTD-PAH including SSc-PAH are limited to one study that evaluated three oral agents (sildenafil, bosentan and sitaxsentan) alone. The findings of this meta-analysis are important because patients with all PAH as well as a subgroup of patients with CTD-PAH were included, and the effects of three types of agent, including intravenous preparations, were thoroughly evaluated. Our meta-analysis shows similar trends to the findings of Avouac et al.

When the mean differences between changes in 6 MWD were compared between all patients with PAH and patients with CTD-PAH, the effects of ERAs (bosentan and ambrisentan) on exercise tolerance may be less in patients with CTD-PAH, whereas no difference in exercise capacity was found between patient groups for PDE-5 inhibitors and PGI2 analogues. This result should be interpreted cautiously because recent data from registries have shown that 6 MWD is significantly lower in patients with CTD-PAH than in those with idiopathic PAH and a systematic review has shown that 6 MWD may be only partially valid in patients with SSc-PAH. This analysis has several limitations. First, we could identify only a limited number of studies for some agents (one study each for tadalafil, ambrisentan and...
Table 2  Summary of included studies evaluating treatment with PAH agents in patients with CTD-PAH

<table>
<thead>
<tr>
<th>Source (official acronym)</th>
<th>PAH agent</th>
<th>Number of patients with CTD-PAH</th>
<th>Number (%) of patients with SSc-PAH</th>
<th>Study design</th>
<th>Intervention</th>
<th>Control</th>
<th>Period (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badesch et al&lt;sup&gt;34&lt;/sup&gt; (SUPER-1)</td>
<td>Sildenafil, Tadalafil</td>
<td>84, 95</td>
<td>38 (45), 52 (79)</td>
<td>RCT, DB</td>
<td>20 mg×3/day, 40 mg×3/day and 80 mg×3/day placebo</td>
<td>Placebo</td>
<td>12</td>
</tr>
<tr>
<td>Denton et al&lt;sup&gt;35&lt;/sup&gt; (PHIRST)</td>
<td>Bosentan</td>
<td>66</td>
<td>52 (79)</td>
<td>RCT, DB</td>
<td>2.5, 10, 20 and 40 mg, 250 mg×2/day placebo</td>
<td>Placebo</td>
<td>16</td>
</tr>
<tr>
<td>Launay et al&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Bosentan</td>
<td>49</td>
<td>49 (100)</td>
<td>Single-arm, open-label</td>
<td>62.5 mg×2/day for 4 weeks, then 125 or 250 mg×2/day placebo</td>
<td>None</td>
<td>28</td>
</tr>
<tr>
<td>Badesch et al&lt;sup&gt;37&lt;/sup&gt; (ARIES)</td>
<td>Ambrisentan</td>
<td>124</td>
<td>49 (100)</td>
<td>RCT, DB</td>
<td>2.5, 5 and 10 mg, 5 mg placebo</td>
<td>Placebo</td>
<td>12</td>
</tr>
<tr>
<td>Badesch et al&lt;sup&gt;38&lt;/sup&gt; (ARIES-3)</td>
<td>Ambrisentan</td>
<td>40</td>
<td>NR</td>
<td>Single-arm, open-label</td>
<td>62.5 mg×2/day for 4 weeks, then 125 or 250 mg×2/day placebo</td>
<td>None</td>
<td>24</td>
</tr>
<tr>
<td>Badesch et al&lt;sup&gt;39&lt;/sup&gt;</td>
<td>Epoprostenol</td>
<td>111</td>
<td>111 (100)</td>
<td>RCT, open-label</td>
<td>Dosage established according to signs and symptoms from initial low dose</td>
<td>Conventional therapy</td>
<td>12</td>
</tr>
<tr>
<td>Kunieda et al&lt;sup&gt;40&lt;/sup&gt;</td>
<td>Beraprost</td>
<td>19</td>
<td>NR</td>
<td>Single-arm, open-label</td>
<td>Initial dose of 120 mg/day, then titrated to maximum dose of 360 mg/day placebo</td>
<td>None</td>
<td>12</td>
</tr>
<tr>
<td>Oudiz et al&lt;sup&gt;41&lt;/sup&gt;</td>
<td>Treprostinil</td>
<td>90</td>
<td>45 (50)</td>
<td>RCT, DB</td>
<td>Initial dosage of 2.5 or 5.0 ng/kg/min, then titrated to maximum dosage of 20 ng/kg/min placebo</td>
<td>Placebo</td>
<td>8</td>
</tr>
</tbody>
</table>

CTD, connective tissue disease; DB, double-blind; NR, not reported; PAH, pulmonary arterial hypertension; RCT, randomised controlled trial; SSc, systemic sclerosis.
Figure 2  Effects of individual pulmonary arterial hypertension (PAH) agents on 6 min walk distance (6 MWD) in patients with any form of PAH. ERA, endothelin receptor antagonist; NA, not applicable; PDE, phosphodiesterase; PGI2, prostacyclin.
independent predictor of prognosis. In addition, investigators who did a placebo-controlled randomised trial of the PDE-5 inhibitor sildenafil have recently identified the minimum clinically meaningful changes in 6 MWD, and concluded that it would be a useful indicator to determine the efficacy of other PAH agents.51

Figure 3 Effects of individual pulmonary arterial hypertension (PAH) agents on 6 min walk distance (6 MWD) in patients with PAH associated with connective tissue disease. ERA, endothelin receptor antagonist; NA, not applicable; PDE, phosphodiesterase; PGI2, prostacyclin. For single-arm studies, the mean changes from baseline are shown.

However, pharmacological treatment for PAH is shifting from monotherapy to combination therapy, and it is expected that clinical studies investigating the efficacy of combination therapy will increase. Therefore, it will be increasingly difficult to do a meta-analysis that includes all the new studies to detect differences between PAH agents. The present analysis is meaningful because it included all available clinical study results to date, and we hope that it contributes to the improvement of the treatment for PAH.

In conclusion, the present meta-analysis of studies that included patients with CTD-PAH showed an increase in 6 MWD by all agents, that is, PDE-5 inhibitors, ERAs and PGI2 analogues. Comparison of the mean differences between changes in 6 MWD suggest that, for bosentan and ambrisentan, the effects on exercise tolerance may differ depending on patient group, whereas the PDE-5 inhibitors sildenafil and tadalafil and the PGI2 analogue epoprostenol show consistent effects regardless of the presence or absence of CTD. Further studies are needed to clarify the clinical implications of these findings.

Contributors NM collected the data and performed the statistical analyses described in this article. NS reviewed the collection and analyses of the data. He helped conceive and design the meta-analysis, interpret the results and revise the manuscript. HW revised the data analyses and drafted the manuscript, providing important intellectual content from the perspective of a CTD-PAH specialist. HW revised the manuscript critically for important intellectual content from the perspective of a PAH specialist. All authors have read and approved the final version of the manuscript.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests MK has received research funding from Actelion Pharmaceuticals, GlaxoSmithKline, Novartis and Pfizer, and lecture fees from Actelion Pharmaceuticals, Pfizer, GlaxoSmithKline, Nippon Shin'yaku, Mitsubishi Tanabe Pharma and Takeda Pharmaceuticals. WH has received research funding from the Ministry of Health, Labour and Welfare of Japan, Teikai Seiyaku, Takeda Pharmaceuticals, Mochida, Pfizer, Astera and Daiichi Sankyo, and lecture fees from Pfizer, Acterion, Novartis, Daich Sankyo, GlaxoSmithKline and Nihon Shin'yaku. NM and NS are employees of Pfizer Japan Inc.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES